1. Home
  2. ABUS vs SMWB Comparison

ABUS vs SMWB Comparison

Compare ABUS & SMWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABUS
  • SMWB
  • Stock Information
  • Founded
  • ABUS 2005
  • SMWB 2007
  • Country
  • ABUS United States
  • SMWB Israel
  • Employees
  • ABUS N/A
  • SMWB N/A
  • Industry
  • ABUS Biotechnology: Pharmaceutical Preparations
  • SMWB Computer Software: Programming Data Processing
  • Sector
  • ABUS Health Care
  • SMWB Technology
  • Exchange
  • ABUS Nasdaq
  • SMWB Nasdaq
  • Market Cap
  • ABUS 611.0M
  • SMWB 695.0M
  • IPO Year
  • ABUS N/A
  • SMWB 2021
  • Fundamental
  • Price
  • ABUS $3.22
  • SMWB $8.63
  • Analyst Decision
  • ABUS Strong Buy
  • SMWB Strong Buy
  • Analyst Count
  • ABUS 4
  • SMWB 8
  • Target Price
  • ABUS $5.50
  • SMWB $15.75
  • AVG Volume (30 Days)
  • ABUS 774.3K
  • SMWB 513.9K
  • Earning Date
  • ABUS 08-04-2025
  • SMWB 08-05-2025
  • Dividend Yield
  • ABUS N/A
  • SMWB N/A
  • EPS Growth
  • ABUS N/A
  • SMWB N/A
  • EPS
  • ABUS N/A
  • SMWB N/A
  • Revenue
  • ABUS $6,403,000.00
  • SMWB $258,017,999.00
  • Revenue This Year
  • ABUS $3.35
  • SMWB $16.87
  • Revenue Next Year
  • ABUS N/A
  • SMWB $14.96
  • P/E Ratio
  • ABUS N/A
  • SMWB N/A
  • Revenue Growth
  • ABUS N/A
  • SMWB 15.06
  • 52 Week Low
  • ABUS $2.71
  • SMWB $5.71
  • 52 Week High
  • ABUS $4.73
  • SMWB $17.64
  • Technical
  • Relative Strength Index (RSI)
  • ABUS 48.90
  • SMWB 54.99
  • Support Level
  • ABUS $3.08
  • SMWB $8.11
  • Resistance Level
  • ABUS $3.30
  • SMWB $9.26
  • Average True Range (ATR)
  • ABUS 0.10
  • SMWB 0.40
  • MACD
  • ABUS 0.01
  • SMWB 0.01
  • Stochastic Oscillator
  • ABUS 50.00
  • SMWB 45.22

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About SMWB Similarweb Ltd.

Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.

Share on Social Networks: